预测免疫性血小板减少症患者接受血小板生成素受体激动剂治疗后的无治疗缓解:韩国队列的真实世界结局
该研究回顾性分析2016至2021年韩国一家三级中心91例接受艾曲泊帕、罗米司亭或两者治疗的复发或难治性免疫性血小板减少症成人患者,总缓解率为93.4%,其中40%达到无治疗持续缓解;最大缓解时血小板计数>100×10^9/L(OR 5.28,P=.005)和既往静脉注射免疫球蛋白有效(OR 3.93,P=.036)与无治疗持续缓解显著相关。
要点
- 总缓解率93.4%,其中40%达到无治疗持续缓解。
- 最大缓解时血小板计数>100×10^9/L与无治疗持续缓解相关(OR 5.28,P=.005)。
- 既往静脉注射免疫球蛋白有效与无治疗持续缓解相关(OR 3.93,P=.036)。
核心结论
- 血小板生成素受体激动剂在复发或难治性免疫性血小板减少症中显示出稳健疗效和实现无治疗持续缓解的潜力。
- 基线免疫状态和既往静脉注射免疫球蛋白反应可能指导治疗选择和停药策略。
- 这些发现强调个体化免疫性血小板减少症管理的重要性,并为持续难治患者提示未来方向。
研究设计与样本
- 回顾性分析2016至2021年韩国一家三级中心91例接受艾曲泊帕、罗米司亭或两者治疗的成人复发或难治性免疫性血小板减少症患者。
- 评估临床缓解、血小板计数轨迹、疗效丧失及血小板生成素受体激动剂治疗后的无治疗持续缓解。
- 亚组分析识别缓解和无治疗持续缓解率的预测因素。
主要发现
- 总缓解率为93.4%,其中40%达到无治疗持续缓解。
- 最大缓解时血小板计数>100×10^9/L与无治疗持续缓解显著相关(OR 5.28,P=.005)。
- 既往静脉注射免疫球蛋白有效与无治疗持续缓解显著相关(OR 3.93,P=.036)。
- 尽管罗米司亭组最大缓解时血小板计数显著更高,艾曲泊帕与罗米司亭的缓解率和无治疗持续缓解率相当。
- 高自身免疫负荷或静脉注射免疫球蛋白反应差的患者疗效丧失率更高、无治疗持续缓解率更低。
关键数值与推荐
- 总缓解率93.4%。
- 无治疗持续缓解率40%。
- 最大缓解时血小板计数>100×10^9/L:OR 5.28,P=.005。
- 既往静脉注射免疫球蛋白有效:OR 3.93,P=.036。
临床怎么用
- 作者认为基线免疫状态和既往静脉注射免疫球蛋白反应可能指导治疗选择和停药策略。
- 作者认为这些发现强调个体化免疫性血小板减少症管理的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thrombopoietin receptor agonists (TPO-RAs) have become a cornerstone in the management of relapsed or refractory immune thrombocytopenia (R/R-ITP), with emerging evidence supporting treatment discontinuation in selected patients. However, predictors of sustained response and real-world switching patterns remain underexplored in Asian populations. OBJECTIVES: To evaluate clinical outcomes, switching strategies, and predictors of treatment-free remission following TPO-RA therapy in Korean patients with R/R-ITP. METHODS: We retrospectively analyzed 91 adult R/R-ITP patients treated with eltrombopag, romiplostim (ROMI), or both at a tertiary center in Korea from 2016 to 2021. Clinical responses, platelet count trajectories, loss of response, and sustained response off treatment (SROT) after TPO-RA were assessed. Subgroup analyses identified predictors for response and SROT rates. Notably, Korean reimbursement guidelines mandating drug interruption every 6 months facilitated longitudinal assessment of treatment-free outcomes. RESULTS: The overall response rate was 93.4%, and 40% of those achieved SROT after TPO-RA. Higher peak platelet count (platelet count at maximal response > 100 × 109/L; odds ratio, 5.28; P = .005) and prior intravenous immunoglobulin (IVIG) responsiveness (odds ratio, 3.93; P = .036) were significantly associated with SROT. Despite a significantly higher platelet count at maximal response with ROMI, response and SROT rates were comparable between eltrombopag and ROMI, likely reflecting differences in dosing and adherence patterns. Patients with high autoimmune burden or poor IVIG response showed higher loss of response and lower SROT rates. CONCLUSION: TPO-RAs demonstrated robust efficacy and potential for SROT in R/R-ITP. Baseline immunologic status and prior IVIG response may guide treatment selection and discontinuation strategies. These findings highlight the importance of individualized immune thrombocytopenia management and suggest future directions for patients with persistent refractoriness.
引用
- Yoon JH, Lee S, Kwag D, et al. Predicting treatment-free remission after thrombopoietin receptor agonist therapy in immune thrombocytopenia: real-world outcomes from a Korean cohort. J Thromb Haemost. 2025. PMID: 41407157. doi:10.1016/j.jtha.2025.11.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。